Literature DB >> 33820978

Restorative effects of red onion (Allium cepa L.) juice on erectile function after-treatment with 5α-reductase inhibitor in rats.

Didem Yilmaz-Oral1, Alev Onder2, Ecem Kaya-Sezginer3, Cetin Volkan Oztekin4, Murat Zor5, Serap Gur6.   

Abstract

Benign prostatic hyperplasia (BPH) is one of the most prevalent conditions among aged men. The use of 5α-reductase inhibitors (5-ARIs) to treat BPH was linked to erectile dysfunction (ED). Many medicinal plants and secondary metabolites are used in the management of ED. Onion (Allium cepa L.) is an economically affordable vegetable with vital phytochemicals and biological functions. The study aimed to identify the beneficial effects of onion juice on dutasteride (a 5-ARI)-induced ED. Rats were divided into two groups (n = 5 per group): control and dutasteride-treated rats (0.5 mg/kg/day). Dutasteride was administered in drinking water for 12 weeks. Experiments were performed at the end of the 12th week. In vivo erectile responses were measured before and after intracavernosal injection of onion. Relaxant responses to onion juice were examined in the corpus cavernosum (CC). Acetylcholine (ACh)-, electrical field stimulation (EFS)-, sodium nitroprusside (SNP)-induced relaxation responses in CC tissues were evaluated in the absence and presence of onion juice. Total intracavernosal pressure (ICP) and ICP/ mean arterial pressure were significantly reduced in dutasteride-treated rats (1881.14 ± 249.72 mmHg, P < 0.001;0.26 ± 0.03, P < 0.01) as compared to control rats (4542.60 ± 429.19 mmHg, 0.51 ± 0.05), which was normalized after the intracavernous administration of onion (3288.60 ± 185.45 mmHg, 0.58 ± 0.04). Onion markedly induced relaxant responses in control (72.5 ± 4.7) and dutasteride-treated (66.5 ± 2.7) groups after precontraction with phenylephrine. Relaxation responses to onion were partially inhibited after precontraction with KCl (32.5 ± 3.1, P < 0.001). The relaxant responses to ACh (14.9 ± 4.2, P < 0.01) were diminished in dutasteride-treated CC) compared to control CC (59.8 ± 3.4), which was enhanced after the incubation with onion (36.6 ± 4.8). There were no differences in relaxation response to SNP among all groups. However, relaxation response to SNP was reduced in dutasteride-treated CC at 1 μM (P < 0.05) and 10 μM dosages (P < 0.001), which was partially increased after the incubation with onion at 10 μM dosage (P < 0.01). The presence of onion did not change the reduction in EFS-caused relaxation in the dutasteride-treated group. The current data suggest that red onion juice has a restorative effect on erectile function and endothelium-dependent relaxation response following the treatment of dutasteride.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33820978     DOI: 10.1038/s41443-021-00421-y

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  47 in total

1.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

2.  Assessing finasteride-associated sexual dysfunction using the FAERS database.

Authors:  A K Gupta; J Carviel; M A MacLeod; N Shear
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-04-03       Impact factor: 6.166

3.  Histology of the prostate in elderly men. A study in an autopsy series.

Authors:  T B Harbitz; O A Haugen
Journal:  Acta Pathol Microbiol Scand A       Date:  1972

Review 4.  EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Authors:  Matthias Oelke; Alexander Bachmann; Aurélien Descazeaud; Mark Emberton; Stavros Gravas; Martin C Michel; James N'dow; Jørgen Nordling; Jean J de la Rosette
Journal:  Eur Urol       Date:  2013-03-13       Impact factor: 20.096

5.  Clinical evaluation of benign prostatic hyperplasia.

Authors:  Kevin T McVary
Journal:  Rev Urol       Date:  2003

6.  Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.

Authors:  Kazuyoshi Shigehara; Tohru Miyagi; Takao Nakashima; Koji Izumi; Yasuhide Kitagawa; Atsushi Mizokami; Eitetsu Koh; Masayoshi Shimamura; Mikio Namiki
Journal:  Aging Male       Date:  2016-02-18       Impact factor: 5.892

Review 7.  Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.

Authors:  G Corona; G Tirabassi; D Santi; E Maseroli; M Gacci; M Dicuio; A Sforza; E Mannucci; M Maggi
Journal:  Andrology       Date:  2017-04-28       Impact factor: 3.842

8.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

Authors:  Richard V Clark; David J Hermann; Glenn R Cunningham; Timothy H Wilson; Betsy B Morrill; Stuart Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

9.  Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.

Authors:  Solam Lee; Young Bin Lee; Sung Jay Choe; Won-Soo Lee
Journal:  Acta Derm Venereol       Date:  2019-01-01       Impact factor: 4.437

10.  Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.

Authors:  Antonio Alcaraz; Joaquín Carballido-Rodríguez; Miguel Unda-Urzaiz; Rafael Medina-López; José L Ruiz-Cerdá; Federico Rodríguez-Rubio; Darío García-Rojo; Francisco J Brenes-Bermúdez; José M Cózar-Olmo; Víctor Baena-González; José Manasanch
Journal:  Int Urol Nephrol       Date:  2016-01-25       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.